1

CURRICULUM VITAE - Inge Marie Svane, Professor, MD, PhD

WORK ADDRESS Center for Cancer Immune Therapy (CCIT), Department of Haematology 54P4 and Department of Oncology 54B1, Copenhagen University Hospital Herlev, Herlev Ringvej 75, 2730 Herlev, Denmark. Phone: +45 38 68 21 31 Fax: +45 44 53 01 76. E-mail: Inge.Marie.Svane@regionh.dk ORCiD: 0000-0002-9451-6037 BIOGRAPHICAL DATA Born: 1964 Nationality: Danish

EDUCATION & SCIENTIFIC EMPLOYMENTS 2010- Chairman, PhD programme in Clinical Cancer Research, University of Copenhagen. 2009- Professor, Clinical Cancer Immune Therapy, the Faculty of Health and Medical

Sciences, University of Copenhagen. 2006- Director, Center for Cancer Immune Therapy (CCIT), Dept. of Haematology, Copenhagen University Hospital Herlev. 2006 Research Leader, the Research Laboratory, Dept. of Haematology, Copenhagen University Hospital Herlev. 2005 Member of the committee, Danish Graduate School in Clinical Oncology. 2004 Group Head, the Immunotherapy Group, Copenhagen University Hospital Herlev. 2003 Senior Scientist, Dept. of Oncology/Haematology, Copenhagen University Hospital Herlev. 1998 Post Doc, Dept. of Oncology/Haematology, Copenhagen University Hospital Herlev. 1997 Ph.D. Title of thesis: "Immune Selection in Murine Tumors", University of Copenhagen. 1992 MD, the Faculty of Health Sciences, University of Copenhagen.

CLINICAL EMPLOYMENTS 2008- Consultant, Dept. of Oncology, Copenhagen University Hospital Herlev. 2007-2008 Educational employment at the Dept. of Internal Medicine, Copenhagen University Hospital Herlev. 2007 Clinical Teacher, the Faculty of Health Sciences, University of Copenhagen. 2002- 2007 Educational employment at Dept. of Oncology, Copenhagen University Hospital Herlev. 1997-1998 Educational employment at Dept. of Oncology, Copenhagen University Hospital

Herlev. 1997 Authorisation for independent medical practice. Aut. no: 00NW5.

LEAVE PERIODS 01.08.99-01.04.00 Maternity leave 01.12.93-01.07.94 Maternity leave

CLINICAL FOCUS AREA Focus of expertise is treatment of melanoma, T-cell based adoptive cell therapy and other cellular therapies, cancer vaccines, and immune regulation.

2

Head of medical treatment of melanoma in Eastern Denmark. Member of the Danish Melanoma Group, responsible for national treatment guidelines. Member of the EORTC Melanoma Group. Head of Immunotherapy, Dept. of Oncology, Copenhagen University Hospital Herlev. Director of GMP immune cell production, Copenhagen University Hospital Herlev. Since 2001 initiator of more than 17 phase I, II, and III immunotherapeutic trials as Sponsor or Principle Investigator (List of clinical trials). Investigator and co-investigator on several international clinical trials in collaboration with the pharmaceutical industry.

CENTER FOR CANCER IMMUNE THERAPY-CCIT CCIT has a focus on the development of immunological treatment of cancer and has a research profile based on equally weighted experimental and clinical projects with a tight interconnection (CCIT homepage). CCIT has around 50 employees, including scientific and technical staff, and comprises a GMP certified laboratory for the preparation of therapeutic immunological cellular products. CCIT has in 2018 been appointed National Center for Cancer Immune Therapy (CCIT-DK).

FUNDING Co-chair of CIRCUIT (Center for Pediatric Cancer Immune Therapy - CIRCUIT): 2018 – 2021, granted 6 mio. DKK from Børnecancerfonden (the Danish Child Cancer Society). Partner in NeoPepVac (Personalized cancer immunotherapy using adjuvanted Neoepitope Peptide based Vaccines): 2018-2021, granted 18,998,376 DKK from the Innovation Fund Denmark. Partner in ‘A personalized approach for increased clinical efficacy of cancer immunotherapy’: 2018-2021, granted 6 mio. DKK from the Neye Foundation. Partner in POLYNANO (Precision and Nano-scale Polymer Mass Replication of Biochips): 2011-16, granted 37 mio. DKK from the Danish Strategic Research Council. Partner in EU project IMMOMEC (Immune modulating strategies for treatment of Merkel cell carcinoma): 2011-15, granted 5.7 mio. € from FP7-Health-2011. Partner in ACT (Development and clinical evaluation of new strategies for adoptive cell transfer (ACT) in the treatment of cancer): 2009-12, granted 12 mio. DKK from the Danish Strategic Research Council. Partner in CEMIK Innovation Consortium (Micro-technological immune therapy of cancer): 2007-10, granted 10.3 mio. DKK from the Danish Agency for Science Technology and Innovation. In addition, larger grants have been granted from Danielsens Foundation, the Danish Cancer Society, the Danish Council for Independent Research - Medical Sciences, the Lundbeck Foundation, and Gerda and Aage Haensch’s Foundation, among others. SUPERVISION AND TEACHING Since 2002, pre-graduate and postgraduate teaching at the Faculty of Health and Medical Sciences, University of Copenhagen. Invited speaker in Denmark and other European countries. Chair for national and Nordic courses and ESMO educational sessions on immunotherapeutic topics. Co-responsible for the Danish guidelines for management of checkpoint inhibitor toxicity (including an app: ImmunTox.dk). Supervisor for numerous pre-graduate students, and at the moment seven PhD-students (MD and M.Sc.) and three post doc/juniors. Defended theses: Troels Holz Borch: Evaluation of immune responses to dendritic cell vaccination and adoptive cell therapy, 2018. Rikke Andersen: Exploiting tumor-infiltrating lymphocytes for the treatment of cancer, 2017.

3

Per Kongsted: Taxane-based chemotherapy and dendritic cell therapy in metastatic castration-resistant prostate cancer, 2017. Jon Bjørn: Ipilimumab in the treatment of metastatic malignant melanoma, 2015. Caroline Hasselbalch Riley: Immunological phenotype in patients with JAK2V617F – positive chronic

myeloproliferative neoplasms. Impact of immune therapy with Interferon-, 2014. Marco Donia: Methods to improve adoptive T cell therapy with tumor infiltrating lymphocytes, 2013. Trine Zeeberg Buch: Immune modulations during chemo-immunotherapy and novel vaccine strategies in metastatic melanoma and NSCLC, 2013. Eva Ellebæk: Dendritic cell vaccination and adoptive cell therapy in patients with metastatic malignant melanoma, 2012. Lotte Engell-Nørregaard: Dendritic cell vaccination of patients with metastatic malignant melanoma, 2011. Niels Junker: Ex vivo expansion and characterization of tumor infiltrating lymphocyte derived T effector memory cells from malignant melanoma and oral squamous cell carcinoma, 2011. Anna Tsakiri: Clinical and immunological efficacy of treatment with simvastatin, 2011. Özcan Met: Exploiting the immunogenic potential of mRNA electroporated dendritic cells. Implication for cancer immunotherapy using selected tumor antigens associated with human breast cancer, 2008. Marie Brimnes: Identification and functional characterization of human dendritic cells and regulatory T cells in multiple myeloma patients, 2008. Annika Berntsen: Dendritic cell vaccination of patients with metastatic renal cell carcinoma, 2008. SCIENTIFIC COLLABORATIONS AND ASSIGNMENTS CCIT has an extensive cooperative network with scientists and oncologists; internally at the hospital, nationally, and internationally. At the moment, CCIT is partner to two EU projects. Chair/Co-chairman, Scientific Committee, Copenhagen University Hospital Herlev, 2005-. Member of Strategic Research Council/FIRU/the scientific advisory board in the Capital Region of Denmark 2007-. Member of the scientific committee, Danish Cancer Society, 2016-. Member of the steering committee, Danish Cancer Research Foundation, 2014-17. Member of the steering committee, Danish Society for Clinical Oncology, 2012-17. Member of ESMO scientific committee, and member of ASCO and SITc. Member of the scientific committee, the Immuno-Oncology Academy of the European Cancer Patient Coalition (ECPC). Member of the editorial board of Cancer Immunology and Immunotherapy and PLoS ONE. Reviewer for Clinical Cancer Research, PLoS ONE, Cancer Immunology and Immunotherapy, Vaccine a.o. Reviewer of scientific applications in Denmark and internationally e.g. the Norwegian Cancer Society, Cancer Research UK, VLK Belgium, The Netherlands’ organisation for health research and development, FWO The Netherlands, and SIRIC France. Co-organizer of the Danish Cancer Society Symposium 2013, held in Copenhagen in September 2013. SCIENTIFIC AWARDS 2001 Prize of honour awarded by Brinchs Legat 2010 Merit Award by Hede Nielsens Foundation 2013 Global Excellence in Health Award, the Capital Region of Denmark 2015 Prize of honour awarded by Lise and Gunnar Waerums Foundation 2017 Prize of honour awarded by The Danish Cancer Society 2017 Prize of honour awarded by J. and L. Dannins Legat COMMERCIALIZATION

4

CCIT is sponsoring phase I, first-in-man studies, establishing proof-of-concept for CCIT based inventions. Recently, the early development of an IDO targeting peptide vaccine was supported by a proof-of-concept grant, and based on promising phase I trial data, an immuno-oncology company, IO Biotech, was spun out of CCIT in January 2015 with seed funding from Novo Seed and Lundbeck Merge. NETWORK AND COMMUNICATION Key opinion leader on cancer immunotherapy, acknowledging the importance of communication to the public, patient associations, and politicians. Founder and leader of the cross-disciplinary network for research in cancer immunotherapy IMMUNONET, 2018-. Founder and Chair of the Clinical Academic Group in Cancer Immunotherapy (CAGci), 2018-.

5

PUBLICATIONS Author/co-author on 172 published/accepted scientific papers. July 2018, Web of Science: citations 3860, h-index 34

1. Petersen BL, Engel AM, Juul-Madsen H, Mouritsen S, Svane I, and Werdelin O. Tumors developing in nude mice express unusually large amounts of MHC class I antigens. APMIS, 99(7-12):1111-9. doi: 10.1111/j.1699-0463.1991.tb01308.x. 1991.

2. Petersen BL, Petersen CL, Braendstrup O, Mouritsen S, Engel AM, Svane IM, and Werdelin O. Expression of

beta2-microglobulin by premalignant epithelium. APMIS, 101(7-12):529-36. doi: 10.1111/j.1699-0463.1993.tb00142.x. 1993.

3. Mouritsen S, Dalum I, Engel AM, Svane IM, Werdelin O, and Elsner H. MHC class II-bound self-peptides can

be effectively separated by isoelectric focusing and bind optimally to their MHC class II restriction elements around pH 5.0. Immunology, 82(4):529-34. 1994.

4. Engel AM, Svane IM, Mouritsen S, Rygaard J, Clausen J, and Werdelin O. Methylcholanthrene-induced sarcomas in nude mice have short induction times and relatively low levels of surface MHC class I expression. APMIS, 104(7-8):629-39. doi: 10.1111/j.1699-0463.1996.tb04923.x. 1996.

5. Svane IM, Engel AM, Nielsen MB, Ljunggren HG, Rygaard J, and Werdelin O. Chemically induced sarcomas

from nude mice are more immunogenic than similar sarcomas from congenic normal mice. Eur J Immunol, 26(8):1844-50. doi: 10.1002/eji.1830260827. 1996.

6. Engel AM, Svane IM, Rygaard J, and Werdelin O. MCA sarcomas induced in scid mice are more

immunogenic than MCA sarcomas induced in congenic, immunocompetent mice. Scand J Immunol, 45(4):463-70. doi: 10.1046/j.1365-3083.1997.d01-419.x. 1997.

7. Svane IM, Engel AM, Thomsen AR, and Werdelin O. The susceptibility to cytotoxic T lymphocyte mediated

lysis of chemically induced sarcomas from immunodeficient and normal mice. Scand J Immunol, 45(1):28-35. doi: 10.1046/j.1365-2249.1997.4361335.x. 1997.

8. Engel AM, Svane IM, Madsen MW, Pedersen M, and Werdelin O. Molecular aberrations in the MHC class I-

restricted pathway for antigen presentation in methylcholanthrene sarcomas from nude mice: discrepancies between MHC mRNA and surface protein. Clin Exp Immunol, 109(2):323-31. doi: 10.1046/j.1365-2249.1997.4361335.x. 1997.

9. Svane IM, Engel AM, Nielsen M, and Werdelin O. Interferon-gamma-induced MHC class I expression and

defects in Jak/Stat signalling in methylcholanthrene-induced sarcomas. Scand J Immunol, 46(4):379-87. doi: 10.1046/j.1365-3083.1997.d01-141.x. 1997.

10. Engel AM, Svane IM, Rygaard J, and Werdelin O. Immune selection in murine tumors. A study of MCA

induced sarcomas in normal and immunodeficient mice. Folia Microbiol (Praha), 43(5):483-6. doi: 10.1007/BF02820798. 1998.

11. Svane IM, Engel AM, Thomsen NB, Wulf HC, and Werdelin O. High MHC class I expression correlates with

slow growth in UV-induced skin carcinomas in hairless mice. APMIS, 106(11):1101-7. doi: 10.1111/j.1699-0463.1998.tb00265.x. 1998.

12. Svane IM, Boesen M, and Engel AM. The role of cytotoxic T-lymphocytes in the prevention and immune

surveillance of tumors--lessons from normal and immunodeficient mice. Med Oncol, 16(4):223-38. doi: 10.1007/BF02785868. 1999.

13. Boesen M, Svane IM, Engel AM, Rygaard J, Thomsen AR, and Werdelin O. CD8+ T cells are crucial for the

ability of congenic normal mice to reject highly immunogenic sarcomas induced in nude mice with 3-

6

methylcholanthrene. Clin Exp Immunol, 121(2):210-5. doi: 10.1046/j.1365-2249.2000.01292.x. 2000.

14. Svane IM, Nikolajsen K, Hansen SW, Kamby C, Nielsen DL, and Johnsen HE. Impact of high-dose chemotherapy on antigen-specific T cell immunity in breast cancer patients. Application of new flow cytometric method. Bone Marrow Transplant, 29(8):659-66. doi: 10.1038/sj.bmt.1703521. 2002.

15. Svane IM, Homburg KM, Kamby C, Nielsen DL, Roer O, Sliffsgaard D, Johnsen HE, and Hansen SW. Acute

and Late Toxicity Following Adjuvant High-Dose Chemotherapy for High-Risk Primary Operable Breast Cancer A Quality Assessment Study. Acta Oncol, 41(7-8):675-683. doi: 10.1080/028418602321028300. 2002.

16. Svane IM and Engel AM. Immune selection in murine tumours. Ph.d thesis. APMIS Suppl., (106):1-46. 2003.

17. Svane IM, Soot ML, Buus S, and Johnsen HE. Clinical application of dendritic cells in cancer vaccination

therapy. APMIS, 111(7-8):818-34. doi: 10.1034/j.1600-0463.2003.11107813.x. 2003.

18. Reker S, Meier A, Holten-Andersen L, Svane IM, Becker JC, thor Straten P, and Andersen MH. Identification of novel survivin-derived CTL epitopes. Cancer Biol Ther, 3(2):173-9. doi: 10.4161/cbt.3.2.611.2004.

19. Reker S, Becker JC, Svane IM, Ralfkiaer E, Straten PT, and Andersen MH. HLA-B35-restricted immune

responses against survivin in cancer patients. Int J Cancer, 108(6):937-41. doi: 10.1002/ijc.11634. 2004.

20. Svane IM, Pedersen AE, Johnsen HE, Nielsen D, Kamby C, Gaarsdal E, Nikolajsen K, Buus S, and Claesson MH. Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study. Cancer Immunol Immunother, 53(7):633-41. doi: 10.1007/s00262-003-0493-5. 2004.

21. Do TH, Johnsen HE, Kjaersgaard E, Taaning E, and Svane IM. Impaired circulating myeloid DCs from

myeloma patients. Cytotherapy, 6(3):196-203. doi: 10.1080/14653240410006004. 2004.

22. Nielsen DL and Svane IM. [High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review]. Ugeskr Laeger, 166(46):4148-50. Danish. 2004.

23. Nielsen DL and Svane IM. [High dose chemotherapy versus conventional chemotherapy in metastasing

breast cancer: An analysis of a systematic Cochrane review]. Ugeskr Laeger, 166(46):4145-7. Danish. 2004.

24. Meier A, Reker S, Svane IM, Holten-Andersen L, Becker JC, Søndergaard I, Andersen MH, and Thor Straten P. Spontaneous T-cell responses against peptides derived from the Taxol resistance-associated gene-3 (TRAG-3) protein in cancer patients. Cancer Immunol Immunother, 54(3):219-28. doi: 10.1007/s00262-004-0578-9. 2005.

25. Andersen MH, Svane IM, Kvistborg P, Nielsen OJ, Balslev E, Reker S, Becker JC, and Straten PT.

Immunogenicity of Bcl-2 in patients with cancer. Blood, 105(2):728-34. doi: 10.1182/blood-2004-07-2548. 2005.

26. Pedersen AE, Thorn M, Gad M, Walter MR, Johnsen HE, Gaarsdal E, Nikolajsen K, Buus S, Claesson MH, and

Svane IM. Phenotypic and functional characterization of clinical grade dendritic cells generated from patients with advanced breast cancer for therapeutic vaccination. Scand J Immunol, 61(2):147-56. doi: 10.1111/j.0300-9475.2005.01531.x. 2005.

27. Svane IM, Nikolajsen K, Walter MR, Buus S, Gad M, Claesson MH, and Pedersen AE. Characterization of

monocyte-derived dendritic cells maturated with IFN-alpha. Scand J Immunol, 63(3):217-22. doi: 10.1111/j.1365-3083.2006.01728.x. 2006.

28. Svane IM, Berntsen A, Trepiakas R, and Pedersen AE. [Dendrite cell-based cancer vaccines—clinical

7

application]. Ugeskr Laeger, 168(14):1415-20. Danish. 2006.

29. Brimnes MK, Svane IM, and Johnsen HE. Impaired functionality and phenotypic profile of dendritic cells from patients with multiple myeloma. Clin Exp Immunol, 144(1):76-84. doi: 10.1111/j.1365-2249.2006.03037.x. 2006.

30. Berntsen A, Geertsen PF, and Svane IM. Therapeutic dendritic cell vaccination of patients with renal cell

carcinoma. Eur Urol, 50(1):34-43. doi: 10.1016/j.eururo.2006.03.061. 2006.

31. Sørensen RB, Hadrup SR, Køllgaard T, Svane IM, thor Straten P, and Andersen MH. Efficient tumor cell lysis mediated by a Bcl-X(L) specific T cell clone isolated from a breast cancer patient. Cancer Immunol Immunother, 56(4):527-33. doi: 10.1007/s00262-006-0200-4. 2007.

32. Svane IM, Pedersen AE, Johansen JS, Johnsen HE, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E,

Nikolajsen K, and Claesson MH. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother, 56(9):1485-99. doi: 10.1007/s00262-007-0293-4. 2007.

33. Andersen MH, Svane IM, Becker JC, and Straten PT. The universal character of the tumor-associated

antigen survivin. Clin Cancer Res, 13(20):5991-4. doi: 10.1158/1078-0432.CCR-07-0686. 2007.

34. Svane IM, Nikolajsen K, and Johnsen HE. Antigen-specific T-cell immunity in multiple myeloma patients is restored following high-dose therapy: implications for timing of vaccination. Scand J Immunol, 66(4):465-75. doi: 10.1111/j.1365-3083.2007.01993.x. 2007.

35. Wenandy L, Sørensen RB, Sengeløv L, Svane IM, thor Straten P, and Andersen MH. The immunogenicity of

the hTERT540-548 peptide in cancer. Clin Cancer Res, 14(1):4-7. doi: 10.1158/1078-0432.CCR-07-4590. 2008.

36. Andersen MH, Sørensen RB, Schrama D, Svane IM, Becker JC, and Thor Straten P. Cancer treatment: the

combination of vaccination with other therapies. Cancer Immunol Immunother, 57(11):1735-43. doi: 10.1007/s00262-008-0480-y. 2008.

37. Kvistborg P, Hadrup SR, Svane IM, Andersen MH, and Straten PT. Characterization of a single peptide

derived from cytochrome P450 1B1 that elicits spontaneous human leukocyte antigen (HLA)-A1 as well as HLA-B35 restricted CD8 T-cell responses in cancer patients. Hum Immunol, 69(4-5):266-72. doi: 10.1016/j.humimm.2008.02.007. 2008.

38. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson

MH, Lorentzen T, Johansen JS, and Svane IM. Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother, 31(8):771-80. doi: 10.1097/CJI.0b013e3181833818. 2008.

39. Trepiakas R, Pedersen AE, Met O, Hansen MH, Berntsen A, and Svane IM. Comparison of alpha-Type-1

polarizing and standard dendritic cell cytokine cocktail for maturation of therapeutic monocyte-derived dendritic cell preparations from cancer patients. Vaccine, 26(23):2824-32. doi: 10.1016/j.vaccine.2008.03.054. 2008.

40. Wenandy L, Sørensen RB, Svane IM, Thor Straten P, and Andersen MH. RhoC a new target for therapeutic

vaccination against metastatic cancer. Cancer Immunol Immunother, 57(12):1871-8. doi: 10.1007/s00262-008-0517-2. 2008.

41. Svane IM, Pedersen AE, Nikolajsen K, and Zocca MB. Alterations in p53-specific T cells and other

lymphocyte subsets in breast cancer patients during vaccination with p53-peptide loaded dendritic cells

8

and low-dose interleukin-2. Vaccine, 26(36):4716-24. doi: 10.1016/j.vaccine.2008.06.085. 2008.

42. Met O, Eriksen J, and Svane IM. Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential. Mol Biotechnol, 40(2):151-60. doi: 10.1007/s12033-008-9071-6. 2008.

43. Sørensen RB, Svane IM, Straten PT, and Andersen MH. A survivin specific T-cell clone from a breast cancer

patient display universal tumor cell lysis. Cancer Biol Ther, 7(12):1885-7. doi: 10.4161/cbt.7.12.6935. 2008.

44. Engell-Noerregaard L, Hansen TH, Andersen MH, Thor Straten P, and Svane IM. Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters. Cancer Immunol Immunother, 58(1):1-14. doi: 10.1007/s00262-008-0568-4. 2009.

45. Vestermark LW, Holtved E, Dahlrot R, Brimnes MK, Svane IM, and Bastholt L. A phase II study of

thalidomide and temozolomide in patients with brain metastases from malignant melanoma: lymphopenia correlates with response. Ecancermedicalscience, 2:91. doi: 10.3332/ecancer.2008.91. 2008.

46. Sørensen RB, Andersen RS, Svane IM, Engell-Noerregaard L, Hadrup SR, Balslev E, Andersen MH, and thor

Straten P. CD8 T-cell responses against cyclin B1 in breast cancer patients with tumors overexpressing p53. Clin Cancer Res, 15(5):1543-9. doi: 10.1158/1078-0432.CCR-08-1412. 2009.

47. Sørensen RB, Junker N, Kirkin A, Voigt H, Svane IM, Becker JC, thor Straten P, and Andersen MH. The

immunodominant HLA-A2-restricted MART-1 epitope is not presented on the surface of many melanoma cell lines. Cancer Immunol Immunother, 58(5):665-75. doi: 10.1007/s00262-008-0588-0. 2009.

48. Trepiakas R, Pedersen AE, Met O, and Svane IM. Addition of interferon-alpha to a standard maturation cocktail

induces CD38 up-regulation and increases dendritic cell function. Vaccine, 27(16):2213-9. doi: 10.1016/j.vaccine.2009.02.015. 2009.

49. Kloverpris H, Karlsson I, Bonde J, Thorn M, Vinner L, Pedersen AE, Hentze JL, Andresen BS, Svane IM, Gerstoft J,

Kronborg G, and Fomsgaard A. Induction of novel CD8+ T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS, 23(11):1329-40. doi: 10.1097/QAD.0b013e32832d9b00. 2009.

50. Wenandy L, Kollgaard T, Letsch A, Andersen RS, Stather D, Seremet T, Svane IM, Vindeløv L, Andersen MH, and

thor Straten P. The 1170 A-P single-nucleotide polymorphism (SNP) in the Her-2/neu protein (HER2) as a minor histocompatibility antigen (mHag). Leukemia, 23(10):1926-9. doi: 10.1038/leu.2009.112. 2009.

51. Andersen MH, Sørensen RB, Brimnes MK, Svane IM, Becker JC, and thor Straten P. Identification of heme

oxygenase-1 specific regulatory CD8+ T cells in cancer patients. J Clin Invest, 119(8):2245-56. doi: 10.1172/JCI38739. 2009.

52. Sørensen RB, Berge-Hansen L, Junker N, Hansen CA, Hadrup SR, Schumacher TN, Svane IM, Becker JC, thor

Straten P, and Andersen MH. The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase. PLoS One, 4(9):e6910. doi: 10.1371/journal.pone.0006910. 2009.

53. Soleimani A, Berntsen A, Svane IM, and Pedersen AE. Immune responses in patients with metastatic renal cell

carcinoma treated with dendritic cells pulsed with tumor lysate. Scand J Immunol, 70(5):481-9. doi: 10.1111/j.1365_3083.2009.02322.x. 2009.

54. Tsakiri A, Tsiantoulas D, Frederiksen J, and Svane IM. Increased immunopotency of monocyte derived dendritic

cells from patients with optic neuritis is inhibited in vitro by simvastatin. Exp Neurol, 221(2):320-8. doi: 10.1016/j.expneurol.2009.11.014. 2010.

9

55. Berntsen A, Brimnes MK, thor Straten P, and Svane IM. Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2. J Immunother, 33(4):425-34. doi: 10.1097/CJI.0b013e3181cd870f. 2010.

56. Larsen SK, Svane IM, thor Straten P, and Andersen MH. Therapeutic Cancer Vaccines. Curr Cancer Ther Rev,

6(2):163-174. doi: 10.2174/157339410791202529. 2010. 57. Trepiakas R, Berntsen A, Hadrup SR, Bjørn J, Geertsen PF, Straten PT, Andersen MH, Pedersen AE, Soleimani A,

Lorentzen T, Johansen JS, and Svane IM. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/ II trial. Cytotherapy, 12(6):721-34. doi: 10.3109/14653241003774045. 2010.

58. Andersen MH, Junker N, Ellebaek E, Svane IM, and Thor Straten P. Therapeutic cancer vaccines in combination

with conventional therapy. J Biomed Biotechnol, 2010:237623. doi: 10.1155/2010/237623. 2010.

59. Brimnes MK, Vangsted AJ, Knudsen LM, Gimsing P, Gang AO, Johnsen HE, and Svane IM. Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR-/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma. Scand J Immunol, 72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x. 2010.

60. Schmidt H, Brown J, Mouritzen U, Selby P, Fode K, Svane IM, Cook GP, Mollerup DH, and Geertsen PF. Safety

and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial. Clin Cancer Res, 16(21):5312-9. doi: 10.1158/1078-0432.CCR-10-1809. 2010.

61. Andersen RS, Sørensen RB, Ritter C, Svane IM, Becker JC, thor Straten P, and Andersen MH. Identification of a

cyclin B1-derived CTL epitope eliciting spontaneous responses in both cancer patients and healthy donors. Cancer Immunol Immunother, 60(2):227-34. doi: 10.1007/s00262-010-0933-y. 2011.

62. Sørensen RB, Hadrup SR, Svane IM, Hjortsø MC, Thor Straten P, and Andersen MH. Indoleamine 2,3-

dioxygenase specific, cytotoxic T cells as immune regulators. Blood, 117(7):2200-10. doi: 10.1182/blood-2010-06-288498. 2011.

63. Met O, Balslev E, Flyger H, and Svane IM. High immunogenic potential of p53 mRNA-transfected dendritic cells

in patients with primary breast cancer. Breast Cancer Res Treat, 125(2):395-406. doi: 10.1007/s10549-010-0844-9. 2011.

64. Hansen M, Hjortø GM, Met O, Jakobsen MH, Svane IM, and Larsen NB. Cell culture plastics with immobilized

interleukin-4 for monocyte differentiation. J Biomed Mater Res A, 96(2):372-83. doi: 10.1002/jbm.a.32986. 2011.

65. Selmeczi D, Hansen TS, Met O, Svane IM, and Larsen NB. Efficient large volume electroporation of dendritic

cells through micrometer scale manipulation of flow in a disposable polymer chip. Biomed Microdevices, 13(2) 383-92. doi: 10.1007/s10544-010-9507-1. 2011.

66. Sørensen RB, Køllgaard T, Andersen RS, van den Berg JH, Svane IM, Straten Pt, and Andersen MH. Spontaneous

cytotoxic T-Cell reactivity against indoleamine 2,3-dioxygenase-2. Cancer Res, 71(6):2038-44. doi: 10.1158/0008-5472.CAN-10-3403. 2011.

67. Bjoern J, Brimnes MK, Andersen MH, Thor Straten P, and Svane IM. Changes in peripheral blood level of

regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2. Scand J Immunol, 73(3):222-33. doi: 10.1111/j.1365-3083.2010.02494.x. 2011.

68. Junker N, Andersen MH, Wenandy L, Dombernowsky SL, Kiss K, Sørensen CH, Therkildsen MH, Von Buchwald C,

Andersen E, Straten PT, and Svane IM. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer. Cytotherapy, 13(7):822-34. doi:

10

10.3109/14653249.2011.563291. 2011.

69. Junker N, Thor Straten P, Andersen MH, and Svane IM. Characterization of ex vivo expanded tumor infiltrating lymphocytes from patients with malignant melanoma for clinical application. J Skin Cancer, 2011:574695. doi: 10.1155/2011/574695. 2011.

70. Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, and Svane IM. Increase in

circulating CD4+CD25+Foxp3+ T cells in patients with Philadelphia-negative chronic myeloproliferative

neoplasms during treatment with IFN-. Blood, 118(8):2170-3. doi: 10.1182/blood-2011-03-340992. 2011.

71. Pedersen AE, Stryhn A, Justesen S, Harndahl M, Rasmussen S, Donskov F, Claesson MH, Pedersen JW, Wandall HH, Svane IM, and Buus S. Wildtype p53-specific antibody and T-cell responses in cancer patients. J Immunother, 34(9) 629-40. doi: 10.1097/CJI.0b013e3182281381. 2011.

72. Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, and Svane IM. Characterization and comparison of

’standard’ and ‘young’ tumor-infiltrating lymphocytesfor adoptive cell therapy at a Danish translational research institution. Scand J Immunol, 75(2):157-67. doi: 10.1111/j.1365-3083.2011.02640.x. 2012.

73. Tsakiri A, Kjærsgaard E, Grigoriadis N, Svane IM, and Frederiksen JL. Effector and regulatory T cells in patients with

acute optic neuritis. Neuroimmunomodulation, 19(2):111-20. doi: 10.1159/000330242. 2012.

74. Munir S, Larsen SK, Iversen TZ, Donia M, Klausen TW, Svane IM, Straten PT, and Andersen MH. Natural CD4+ T-cell responses against indoleamine 2,3-dioxygenase. PLoS One, 7(4):e34568. doi: 10.1371/journal.pone.0034568. 2012.

75. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, Ellebæk E, Svane IM, Schumacher TN, Thor Straten P, and

Hadrup SR. Dissection of T-cell antigen specificity in human melanoma. Cancer Res, 72(7):1642-50. doi: 10.1158/0008-5472.CAN-11-2614. 2012.

76. Junker N, Kvistborg P, Køllgaard T, Straten Pt, Andersen MH, and Svane IM. Tumor associated antigen specific

T-cell populations identified in ex vivo expanded TIL cultures. Cell Immunol, 273(1):1-9. doi: 10.1016/j.cellimm.2011.12.004. 2012.

77. Ellebaek E, Andersen MH, Svane IM, and Straten PT. Immunotherapy for metastatic colorectal cancer: present

status and new options. Scand J Gastroenterol, 47(3):315-24. doi: 10.3109/00365521.2012.640831. 2012.

78. Engell-Noerregaard L, Ellebaek E, Iversen TZ, Hansen TH, Brimnes MK, Met O, Bjoern J, Andersen MH, thor Straten P, and Svane IM. Influence of Metronomic Cyclophosphamide and Interleukine-2 alone or Combined on Blood Regulatory T Cells in Patients with Advanced Malignant Melanoma Treated with Dendritic Cell Vaccines. J Clin Cell Immunol, 3(2):118. doi: 10.4172/2155-9899.1000118. 2012.

79. Brimnes MK, Gang AO, Donia M, Thor Straten P, Svane IM, and Hadrup SR. Generation of autologous tumor-

specific T cells for adoptive transfer based on vaccination, in vitro restimulation and CD3/CD28 dynabead-induced T cell expansion. Cancer Immunol Immunother, 61(8):1221-31. doi: 10.1007/s00262-011-1199-8. 2012.

80. Junker N, Munir S, Kvistborg P, Straten Pt, Svane IM, and Andersen MH. A promiscuous survivin-derived T-cell

epitope restricted to the HLA-A3 super-type alleles. J Invest Dermatol, 132(8):2115-8. doi: 10.1038/jid.2012.109. 2012.

81. Ellebaek E, Engell-Noerregaard L, Iversen TZ, Froesig TM, Munir S, Hadrup SR, Andersen MH, and Svane IM.

Metastatic melanoma patients treated with dendritic cell vaccination, Interleukin-2 and metronomic cyclophosphamide: results from a phase II trial. Cancer Immunol Immunother, 61(10):1791-804. doi: 10.1007/s00262-012-1242-4. 2012.

82. Larsen SK, Hansen M, Svane IM, Straten PT, and Andersen MH. Characterization of Spontaneous Immune

11

Responses against Long Peptides Derived from Bcl-X(L) in Cancer Patients Using Elispot. Cells, 1(2):51-60. doi: 10.3390/cells1020051. 2012.

83. Hansen M, Met Ö, Svane IM, and Andersen MH. Cellular based cancer vaccines: type 1 polarization of dendritic

cells. Curr Med Chem, 19(25):4239-46. doi: 10.2174/092986712802884213. 2012. 84. Donia M, Ellebaek E, Andersen MH, Straten PT, and Svane IM. Analysis of Vδ1 T cells in clinical grade

melanoma-infiltrating lymphocytes. Oncoimmunology, 1(8):1297-1304. doi: 10.4161/onci.21659. 2012.

85. Ellebaek E, Iversen TZ, Junker N, Donia M, Engell-Noerregaard L, Met Ö, Hölmich LR, Andersen RS, Hadrup SR, Andersen MH, thor Straten P, and Svane IM. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J Transl Med, 10(1):169. doi: 10.1186/1479-5876-10-169. 2012.

86. Munir S, Frøsig TM, Hansen M, Svane IM, and Andersen MH. Characterization of T-cell responses against IκBα in

cancer patients. Oncoimmunology, 1(8):1290-1296. doi: 10.4161/onci.21625. 2012. 87. Donia M, Fagone P, Nicoletti F, Andersen RS, Høgdall E, Straten PT, Andersen MH, and Svane IM. BRAF

inhibition improves tumor recognition by the immune system: Potential implications for combinatorial therapies against melanoma involving adoptive T-cell transfer. Oncoimmunology, 1(9):1476–1483. doi: 10.4161/onci.21940. 2012.

88. Engell-Noerregaard L, Hendel HW, Johannesen HH, Alslev L, and Svane IM. FDG PET scans as evaluation of

clinical response to dendritic cell vaccination in patients with malignant melanoma. Cancer Immunol Immunother, 62(1):17-25. doi: 10.1007/s00262-012-1306-5. 2013.

89. Met O and Svane IM. Analysis of surviving-specific T cells in breast cancer patients using human DCs

engineered with survivin mRNA. Methods Mol Biol, 969:275-92. doi: 10.1007/978-1-62703-260-5_17. 2013. 90. Donia M, Hansen M, Sendrup SL, Iversen TZ, Ellebæk E, Andersen MH, Straten Pt, and Svane IM. Methods to

improve adoptive T-cell therapy for melanoma: IFN-γ enhances anticancer responses of cell products for infusion. J Invest Dermatol, 133(2):545-52. doi: 10.1038/jid.2012.336. 2013.

91. Hansen M, Hjortø GM, Donia M, Met Ö, Larsen NB, Andersen MH, thor Straten P, and Svane IM. Comparison of

clinical grade type 1 polarized and standard matured dendritic cells for cancer immunotherapy. Vaccine, 31(4):639-46. doi: 10.1016/j.vaccine.2012.11.053. 2013.

92. Iversen TZ, Brimnes MK, Nikolajsen K, Andersen RS, Hadrup SR, Andersen MH, Bastholt L, and Svane IM.

Depletion of T lymphocytes is correlated with response to temozolomide in melanoma patients. Oncoimmunology, 2(2):e23288. doi: 10.4161/onci.23288. 2013.

93. Munir S, Andersen GH, Met Ö, Donia M, Frøsig TM, Larsen SK, Klausen TW, Svane IM, and Andersen MH. HLA-

restricted CTL that are specific for the immune checkpoint ligand PD-L1 occur with high frequency in cancer patients. Cancer Res, 73(6):1764-76. doi: 10.1158/0008-5472.CAN-12-3507. 2013.

94. Cathelin D, Met Ö, and Svane IM. Silencing of the glucocorticoid-induced leucine zipper improves the

immunogenicity of clinical-grade dendritic cells. Cytotherapy, 15(6):740-9. doi: 10.1016/j.cyt.2013.02.005. 2013.

95. Munir S, Andersen GH, Svane IM, and Andersen MH. The immune checkpoint regulator PD-L1 is a specific

target for naturally occurring CD4+ T cells. Oncoimmunology, 2(4):e23991. doi: 10.4161/onci.23991. 2013.

96. Larsen SK, Munir S, Woetmann A, Frøsig TM, Odum N, Svane IM, Becker JC, and Andersen MH. Functional characterization of Foxp3-specific spontaneous immune responses. Leukemia, 27(12):2332-40. doi: 10.1038/leu.2013.196. 2013.

12

97. Olsen MH, Hjortø GM, Hansen M, Met Ö, Svane IM, and Larsen NB. In-chip fabrication of free-form 3D

constructs for directed cell migration analysis. Lab Chip, 13(24):4800-9. doi: 10.1039/c3lc50930c. 2013.

98. Ellebæk E, Andersen MH, and Svane IM. Cancer Vaccines and the Potential Benefit of Combination with Standard Cancer Therapies. Molecular Vaccines – From Prophylaxis to Therapy, Volume 1, p. 347-359. Springer-Verlag, Wien. doi: 10.1007/978-3-7091-1419-3_20. 2013.

99. Ahmad SM, Larsen SK, Svane IM, and Andersen MH. Harnessing PD-L1-specific cytotoxic T cells for anti-

leukemia immunotherapy to defeat mechanisms of immune escape mediated by the PD-1 pathway. Leukemia, 28(1):236-8. doi: 10.1038/leu.2013.261. 2014.

100. Iversen TZ, Engell-Noerregaard L, Ellebaek E, Andersen R, Larsen SK, Bjoern J, Zeyher C, Gouttefangeas C,

Thomsen BM, Holm B, Thor Straten P, Mellemgaard A, Andersen MH, and Svane IM. Long-lasting disease stabilization in the absence of toxicity in metastatic lung cancer patients vaccinated with an epitope derived from indoleamine 2,3 dioxygenase. Clin Cancer Res, 20(1):221-32. doi: 10.1158/1078-0432.CCR-13-1560. 2014.

101. Donia M, Ellebæk E, and Svane IM. Adoptive T-cell therapy using TILs for the treatment of metastatic

melanoma. Book chapter 22;327-341. Tumor immunology and immunotherapy. Edited by RC Rees. Oxford. doi: 10.1093/med/9780199676866.003.0022. 2014

102. Donia M, Larsen SM, Met O, and Svane IM. Simplified protocol for clinical-grade tumor-infiltrating

lymphocyte manufacturing with use of the Wave bioreactor. Cytotherapy, 16(8):1117-20. doi: 10.1016/j.cyt.2014.02.004. 2014.

103. Ahmad SM, Svane IM, and Andersen MH. The stimulation of PD-L1-specific cytotoxic T lymphocytes can

both directly and indirectly enhance antileukemic immunity. Blood Cancer J, 4:e230. doi: 10.1038/bcj.2014.50. 2014.

104. Andersen R, Nørgaard P, Al-Jailawi MK, and Svane IM. Late development of splenic sarcoidosis-like lesions

in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab. Oncoimmunology, 3(8):e954506. doi: 10.4161/21624011.2014.954506. eCollection 2014.

105. Larsen SK, Ahmad SM, Idorn M, Met Ö, Martinenaite E, Svane IM, Straten PT, and Andersen MH.

Spontaneous presence of FOXO3-specific T cells in cancer patients. Oncoimmunology, 3(8):e953411. doi: 10.4161/21624011.2014.953411. eCollection 2014.

106. Svane IM and Verdegaal EM. Achievements and challenges of adoptive T cell therapy with tumor-

infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Cancer Immunol Immunother, 63(10):1081-91. doi: 10.1007/s00262-014-1580-5. 2014.

107. Pedersen M, Andersen R, Nørgaard P, Jacobsen S, Thielsen P, Thor Straten P, and Svane IM. Successful

treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease. Cancer Immunol Immunother, 63(12):1341-6. doi: 10.1007/s00262-014-1607-y. 2014.

108. Hjortø GM, Olsen MH, Svane IM, and Larsen NB. Confinement dependent chemotaxis in two-photon polymerized linear migration constructs with highly definable concentration gradients. Biomed Microdevices, 17(2):30. doi: 10.1007/s10544-015-9937-x. 2015.

109. Riley CH, Hansen M, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT, Svane IM, and Jensen MK.

Expansion of circulating CD56bright natural killer cells in patients with JAK2-positive chronic

myeloproliferative neoplasms during treatment with interferon-. Eur J Haematol, 94(3):227-34. doi: 10.1111/ejh.12420. 2015.

13

110. Hjortsø MD, Larsen SK, Kongsted P, Met Ö, Frøsig TM, Andersen GH, Ahmad SM, Svane IM, Becker JC,

Straten PT, and Andersen MH. Tryptophan 2,3-dioxygenase (TDO)-reactive T cells differ in their functional characteristics in health and cancer. Oncoimmunology, 4(1):e968480. doi: 10.4161/21624011.2014.968480. eCollection 2015.

111. Iversen TZ, Andersen MH, and Svane IM. The targeting of indoleamine 2,3 dioxygenase -mediated

immune escape in cancer. Basic Clin Pharmacol Toxicol, 116(1):19-24. doi: 10.1111/bcpt.12320. 2015.

112. Tsakiri A, Ravanidis S, Lagoudaki R, Poulatsidou KN, Svane IM, Frederiksen JL, and Grigoriadis N. Neuroprotective and anti-inflammatory mechanisms are activated early in optic neuritis. Acta Neurol Scand, 131(5):305-12. doi: 10.1111/ane.12344. 2015.

113. Andersen MH and Svane IM. Indoleamine 2,3-dioxygenase vaccination. Oncoimmunology, 4(1):e983770.

doi: 10.4161/2162402X.2014.983770. eCollection 2015.

114. Tungatt K, Bianchi V, Crowther MD, Powell WE, Schauenburg AJ, Trimby A, Donia M, Miles JJ, Holland CJ, Cole DK, Godkin AJ, Peakman M, Straten PT, Svane IM, Sewell AK, and Dolton G. Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs. J Immunol, 194(1):463-74. doi: 10.4049/jimmunol.1401785. 2015.

115. Frøsig TM, Lyngaa R, Met Ö, Larsen SK, Donia M, Svane IM, Thor Straten P, and Hadrup SR. Broadening the

repertoire of melanoma-associated T-cell epitopes. Cancer Immunol Immunother, 64(5):609-20. doi: 10.1007/s00262-015-1664-x. 2015.

116. Weber JS, D'Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH Jr, Lao

CD, Linette GP, Thomas L, Lorigan P, Grossmann KF, Hassel JC, Maio M, Sznol M, Ascierto PA, Mohr P, Chmielowski B, Bryce A, Svane IM, Grob JJ, Krackhardt AM, Horak C, Lambert A, Yang AS, and Larkin J. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol, 16(4):375-84. doi: 10.1016/S1470-2045(15)70076-8. 2015.

117. Kongsted P, Svane IM, Lindberg H, Daugaard G, and Sengeløv L. Low-dose prednisolone in first-line

docetaxel for patients with metastatic castration-resistant prostate cancer: is there a clinical benefit? Urol Oncol, 33(11):494.e15-20. doi: 10.1016/j.urolonc.2015.06.022. 2015.

118. Dolton G, Tungatt K, Lloyd A, Bianchi V, Theaker SM, Trimby A, Holland CJ, Donia M, Godkin AJ, Cole DK,

Straten PT, Peakman M, Svane IM, and Sewell AK. More tricks with tetramers: a practical guide to staining T cells with peptide-MHC multimers. Immunology, 146(1):11-22. doi: 10.1111/imm.12499. 2015.

119. Frøsig TM, Yap J, Seremet T, Lyngaa R, Svane IM, Thor Straten P, Heemskerk MH, Grotenbreg GM, and

Hadrup SR. Design and validation of conditional ligands for HLA-B*08:01, HLA-B*15:01, HLA-B*35:01, and HLA-B*44:05. Cytometry A, 87(10):967-75. doi: 10.1002/cyto.a.22689. 2015.

120. Bjoern J, Juul Nitschke N, Zeeberg Iversen T, Schmidt H, Fode K, and Svane IM. Immunological correlates

of treatment and response in stage IV malignant melanoma patients treated with Ipilimumab. Oncoimmunology, 5(4):e1100788. doi: 10.1080/2162402X.2015.1100788. eCollection 2015.

121. Donia M, Andersen R, Kjeldsen JW, Fagone P, Munir S, Nicoletti F, Andersen MH, Thor Straten P, and

Svane IM. Aberrant Expression of MHC Class II in Melanoma Attracts Inflammatory Tumor-Specific CD4+ T-Cells, Which Dampen CD8+ T-cell Antitumor Reactivity. Cancer Res, 75(18):3747-59. doi: 10.1158/0008-5472.CAN-14-2956. 2015.

122. Borch TH, Donia M, Andersen MH, and Svane IM. Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies. Drug Discov Today, 20(9):1127-34. doi:

14

10.1016/j.drudis.2015.07.003. 2015.

123. Andersen R, Donia M, Westergaard MC, Pedersen M, Hansen M, and Svane IM. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma. Hum Vaccin Immunother, 11(12):2790-5. doi: 10.1080/21645515.2015.1075106. 2015.

124. Riley CH, Brimnes MK, Hansen M, Jensen MK, Hasselbalch HC, Kjaer L, Straten PT, and Svane IM.

Interferon-α induces marked alterations in circulating regulatory T cells, NK cell subsets, and dendritic cells in patients with JAK2V617F-positive essential thrombocythemia and polycythemia vera. Eur J Haematol, 97(1):83-92. doi: 10.1111/ejh.12687. 2016.

125. Geukes Foppen MH, Donia M, Svane IM, and Haanen JB. Tumor-infiltrating lymphocytes for the treatment

of metastatic cancer. Mol Oncol, 9(10):1918-35. doi: 10.1016/j.molonc.2015.10.018. 2015.

126. Kongsted P, Svane IM, Lindberg H, Bisbjerg R, Daugaard G, and Sengeløv L. Cabazitaxel as second-line or third-line therapy in patients with metastatic castration-resistant prostate cancer. Anticancer Drugs, 27(7):695-701. doi: 10.1097/CAD.0000000000000375. 2016.

127. Borch TH, Svane IM, and Met Ö. Immune Monitoring Using mRNA-Transfected Dendritic Cells. Methods

Mol Biol, 1428:245-59. doi: 10.1007/978-1-4939-3625-0_16. 2016. 128. Idorn M, Thor Straten P, Svane IM, and Met Ö. Transfection of Tumor-Infiltrating T Cells with mRNA

Encoding CXCR2. Methods Mol Biol, 1428:261-76. doi: 10.1007/978-1-4939-3625-0_17. 2016.

129. Selmeczi D, Hansen TS, Met Ö, Svane IM, and Larsen NB. Large-Scale mRNA Transfection of Dendritic Cells by Electroporation in Continuous Flow Systems. Methods Mol Biol, 1428:151-61. doi: 10.1077/978-1-4939-3625-0_10. 2016.

130. Kongsted P, Svane IM, Lindberg H, and Sengeløv L. Predictors of Chemotherapy-Induced Toxicity and

Treatment Outcomes in Elderly Versus Younger Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 14(6):e559-e568. doi: 10.1016/j.clgc.2016.03.018. 2016.

131. Donia M, Kjeldsen JW, and Svane IM. The controversial role of TNF in melanoma. Oncoimmunology,

5(4):e1107699. doi: 10.1080/2162402X.2015.1107699. eCollection 2016.

132. Bjoern J, Iversen TZ, Nitschke NJ, Andersen MH, and Svane IM. Safety, immune and clinical responses in metastatic melanoma patients vaccinated with a long peptide derived from indoleamine 2,3-dioxygenase in combination with ipilimumab. Cytotherapy, 18(8):1043-55. doi: 10.1016/j.jcyt.2016.05.010. 2016.

133. Kongsted P, Svane IM, Lindberg H, and Sengeløv L. Clinical Impact of the Number of Treatment Cycles in

First-Line Docetaxel for Patients With Metastatic Castration-Resistant Prostate Cancer. Clin Genitourin Cancer, 15(2):e281-e287. doi: 10.1016/j.clgc.2016.08.019. 2016.

134. Andersen R, Donia M, Ellebaek E, Borch TH, Kongsted P, Iversen TZ, Hölmich LR, Hendel HW, Met Ö,

Andersen MH, Thor Straten P, and Svane IM. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Clinical Cancer Research, 22(15):3734-45. doi: 10.1158/1078-0432.CCR-15-1879. 2016.

135. Hölmich LR, Klausen S, Spaun E, Schmidt G, Gad D, Svane IM, Schmidt H, Lorentzen HF, and Ibfelt EH. The

Danish Melanoma Database. Clin Epidemiol, 8:543–548. doi: 10.2147/CLEP.S99484. eCollection 2016.

136. Nitschke NJ, Bjoern J, Met O, Svane IM, and Andersen MH. Therapeutic Vaccination against A Modified Minimal Survivin Epitope Induces Functional CD4 T Cells That Recognize Survivin-Expressing Cells. Scand J Immunol, 84(3):191-3. doi: 10.1111/sji.12456. 2016.

15

137. Boyles TB, Svane IM, Bastholt L, and Schmidt H. [Treatment of BRAF-mutated metastatic melanoma]. Ugeskr Laeger, 178(35):2-5. pii: V02160126. Danish. 2016.

138. Fløe LE, Svane IM, Bastholt L, and Schmidt H. [Immune checkpoint antibodies increase survival in patients

with metastatic melanoma]. Ugeskr Laeger, 178(33):2-5. pii: V01160070. Danish. 2016.

139. Bentzen AK, Marquard AM, Lyngaa R, Saini SK, Ramskov S, Donia M, Such L, Furness AJ, McGranahan N, Rosenthal R, Straten PT. Szallasi Z, Svane IM, Swanton C, Quezada SA, Jakobsen SN, Eklund AC, and Hadrup SR. Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes. Nat Biotechnol, 34(10):1037-1045. doi: 10.1038/nbt.3662. 2016.

140. Munir Ahmad S, Martinenaite E, Hansen M, Junker N, Borch TH, Met Ö, Donia M, Svane IM, and Andersen

MH. PD-L1 peptide co-stimulation increases immunogenicity of a dendritic cell-based cancer vaccine. Oncoimmunology, 5(8):e1202391. doi: 10.1080/2162402X.2016.1202391. eCollection 2016.

141. Hansen M, Met Ö, Larsen NB, Rosenkilde MM, Andersen MH, Svane IM, and Hjortø GM. Autocrine CCL19

blocks dendritic cell migration toward weak gradients of CCL21. Cytotherapy, (9):1187-96. doi: 10.1016/j.jcyt.2016.06.010. 2016.

142. Borch TH, Engell-Noerregaard L, Zeeberg Iversen T, Ellebaek E, Met Ö, Hansen M, Andersen MH, Thor

Straten P, and Svane IM. mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma. Oncoimmunology, 5(9):e1207842. doi: 10.1080/2162402X.2016.1207842. eCollection 2016.

143. Jørgensen NG, Ahmad SM, Abildgaard N, Straten PT, Svane IM, Andersen MH, and Knudsen LM. Peptide

vaccination against multiple myeloma using peptides derived from anti-apoptotic proteins: a phase I trial. Stem Cell Investig, 3:95. doi: 10.21037/sci.2016.11.09. eCollection 2016.

144. Martinenaite E, Munir Ahmad S, Hansen M, Met Ö, Westergaard MW, Larsen SK, Klausen TW, Donia M,

Svane IM, and Andersen MH. CCL22-specific T Cells: Modulating the immunosuppressive tumor microenvironment. Oncoimmunology, 5(11):e1238541. doi: 10.1080/2162402X.2016.1238541. eCollection 2016.

145. Holmström MO, Riley CH, Svane IM, Hasselbalch HC, and Andersen MH. The CALR exon 9 mutations are

shared neoantigens in patients with CALR mutant chronic myeloproliferative neoplasms. Leukemia, 30(12):2413-2416. doi: 10.1038/leu.2016.233. 2016.

146. Holmström MO, Hjortsø MD, Ahmad SM, Met Ö, Martinenaite E, Riley C, Straten P, Svane IM, Hasselbalch

HC, and Andersen MH. The JAK2V617F mutation is a target for specific T cells in the JAK2V617F-positive myeloproliferative neoplasms. Leukemia, 31(2):495-498. doi: 10.1038/leu.2016.290. 2017.

147. Donia M, Pedersen M, and Svane IM. Cancer immunotherapy in patients with preexisting autoimmune

disorders. Semin Immunopathol, 39(3):333-337. doi: 10.1007/s00281-016-0595-8. 2017.

148. Steiniche T, Vestergaard Danielsen A, Wang Z, Feng Y, Switten Nielsen P, Bastholt L, Schmidt H, Svane IM, Dolled-Filhart M, Emancipator K, Weiner R, Busch-Sørensen M, and Zhou W. PD-L1 expression and survival among melanoma patients treated with standard immunotherapy or chemotherapy. J Eur Acad Dermatol Venereol, 31(7):e319-e321. doi: 10.1111/jdv.14106. 2017.

149. Donia M, Kimper-Karl ML, Høyer KL, Bastholt L, Schmidt H, and Svane IM. The majority of patients with

metastatic melanoma are not represented in pivotal phase III immunotherapy trials. Eur J Cancer, 74:89-95. doi: 10.1016/j.ejca.2016.12.017. 2017.

150. Kongsted P, Borch TH, Ellebaek E, Iversen TZ, Andersen R, Met Ö, Hansen M, Lindberg H, Sengeløv L, and

Svane IM. Dendritic cell vaccination in combination with docetaxel for patients with metastatic castration-

16

resistant prostate cancer: A randomized phase II study. Cytotherapy, 19(4):500-513. doi: 10.1016/j.jcyt.2017.01.007. 2017.

151. Ascierto PA, Del Vecchio M, Robert C, Mackiewicz A, Chiarion-Sileni V, Arance A, Lebbé C, Bastholt L,

Hamid O, Rutkowski P, McNeil C, Garbe C, Loquai C, Dreno B, Thomas L, Grob JJ, Liszkay G, Nyakas M, Gutzmer R, Pikiel J, Grange F, Hoeller C, Ferraresi V, Smylie M, Schadendorf D, Mortier L, Svane IM, Hennicken D, Qureshi A, and Maio M. Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol, 18(5):611-622. doi: 10.1016/S1470-2045(17)30231-0. 2017.

152. Bjoern J, Lyngaa R, Andersen R, Rosenkrantz LH, Hadrup SR, Donia M, and Svane IM. Influence of

ipilimumab on expanded tumour derived T cells from patients with metastatic melanoma. Oncotarget, 8(16):27062-27074. doi: 10.18632/oncotarget.16003. 2017.

153. Nitschke NJ, Bjoern J, Iversen TZ, Andersen MH, and Svane IM. Indoleamine 2,3-dioxygenase and survivin

peptide vaccine combined with temozolomide in metastatic melanoma. Stem Cell Investig, 4:77. doi: 10.21037/sci.2017.08.06. eCollection 2017.

154. Buschow SI, Ramazzotti M, Reinieren-Beeren IMJ, Heinzerling LM, Westdorp H, Stefanini I, Beltrame L, Hato SV, Ellebaek E, Gross S, Nguyen VA, Weinlich G, Ragoussis J, Baban D, Schuler-Thurner B, Svane IM, Romani N, Austyn JM, De Vries IJM, Schuler G, Cavalieri D, and Figdor CG. Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phospatidylethanolamine-binding protein 1/Raf kinase inhibitory protein. Oncotarget, 8(40):67439-67456. doi: 10.18632/oncotarget.18698. eCollection 2017.

155. Kjaer L, Holmström MO, Cordua S, Andersen MH, Svane IM, Thomassen M, Kruse TA, Pallisgaard N, Skov

V, and Hasselbalch HC. Sorted peripheral blood cells identify CALR mutations in B- and T-lymphocytes. Leuk Lymphoma, 59(4):973-977. doi: 10.1080/10428194.2017.1359743. 2018.

156. Holmström M, Martinenaite E, Ahmad SM, Met Ö, Friese C, Kjær L, Riley CH, Thor Straten P, Svane IM,

Hasselbalch HC, and Andersen MH. The calreticulin (CALR) exon 9 mutations are promising targets for cancer immune therapy. Leukemia, 32(2):429-437. doi: 10.1038/leu.2017.214. 2018.

157. Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, and Svane IM. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFN-γ Signaling. Cancer Res, 77(17):4562-4566. doi: 10.1158/0008-5472.CAN-16-3172. 2017.

158. Donia M, Kjeldsen JW, Andersen R, Westergaard MCW, Bianchi V, Legut M, Attaf M, Szomolay B, Ott S,

Dolton G, Lyngaa R, Hadrup SR, Sewell AK, and Svane IM. PD-1+ Polyfunctional T Cells Dominate the Periphery after Tumor-Infiltrating Lymphocyte Therapy for Cancer. Clin Cancer Res, 23(19):5779-5788. doi: 10.1158/1078-0432.CCR-16-1692. 2017.

159. Jacquelot N, Roberti MP, Enot DP, Rusakiewicz S, Ternès N, Jegou S, Woods DM, Sodré AL, Hansen M,

Meirow Y, Sade-Feldman M, Burra A, Kwek SS, Flament C, Messaoudene M, Duong CPM, Chen L, Kwon BS, Anderson AC, Kuchroo VK, Weide B, Aubin F, Borg C, Dalle S, Beatrix O, Ayyoub M, Balme B, Tomasic G, Di Giacomo AM, Maio M, Schadendorf D, Melero I, Dréno B, Khammari A, Dummer R, Levesque M, Koguchi Y, Fong L, Lotem M, Baniyash M, Schmidt H, Svane IM, Kroemer G, Marabelle A, Michiels S, Cavalcanti A, Smyth MJ, Weber JS, Eggermont AM, and Zitvogel L. Predictors of responses to immune checkpoint blockade in advanced melanoma. Nat Commun, 8(1):592. doi: 10.1038/s41467-017-00608-2. 2017.

160. Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM,

and Nilsson JA. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model. Nat Commun, 8(1):707. doi: 10.1038/s41467-017-00786-z. 2017.

17

161. Lauss M, Donia M, Harbst K, Andersen R, Mitra S, Rosengren F, Salim M, Vallon-Christersson J, Törngren T,

Kvist A, Ringnér M, Svane IM, and Jönsson G*. Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma. Nat Commun, 8(1):1738. doi: 10.1038/s41467-017-01460-0. 2017. * shared last authorship

162. Kondrup M, Raunkilde L, Svane IM, Schmidt H, and Bastholt L. [Immunotherapy is cancer treatment with a

novel side-effect profile]. Ugeskr Laeger, 179(40):2-6. pii: V05170365. Danish. 2017.

163. Polk A, Svane IM, Andersson M, and Nielsen D. Checkpoint inhibitors in breast cancer – Current status. Cancer Treat Rev, 63:122-134. doi: 10.1016/j.ctrv.2017.12.008. 2018.

164. Andersen R, Westergaard MCW, Kjeldsen JW, Müller A, Pedersen NW, Hadrup SR, Met Ö, Seliger B,

Kromann-Andersen B, Hasselager T, Donia M, and Svane IM. T cell Responses in the Microenvironment of Primary Renal Cell Carcinoma-Implications for Adoptive Cell Therapy. Cancer Immunol Res, 6(2):222-235. doi: 10.1158/2326-6066.CIR-17-0467. 2018.

165. Ahmad SM, Martinenaite E, Holmström M, Jørgensen MA, Met Ö, Nastasi C, Klausen U, Donia M,

Pedersen LM, Munksgaard L, Ødum N, Woetmann A, Svane IM, and Andersen MH. The inhibitory checkpoint, PD-L2, is a target for effector T cells: Novel possibilities for immune therapy. Oncoimmunology, 7(2):e1390641. doi: 10.1080/2162402X.2017.1390641. eCollection 2018. 2017.

166. Martinenaite E, Mortensen REJ, Hansen M, Orebo Holmström M, Munir Ahmad S, Grønne Dahlager

Jørgensen N, Met Ö, Donia M, Svane IM, and Andersen MH. Frequent adaptive immune responses against arginase-1. Oncoimmunology, 7(3):e1404215. doi: 10.1080/2162402X.2017.1404215. eCollection 2018. 2017.

167. Rius C, Attaf M, Tungatt K, Bianchi V, Legut M, Bovay A, Donia M, Thor Straten P, Peakman M, Svane IM,

Ott S, Connor T, Szomolay B, Dolton G, and Sewell AK. Peptide-MHC Class I Tetramers Can Fail To Detect Relevant Functional T Cell Clonotypes and Underestimate Antigen-Reactive T Cell Populations. J Immunol, 200(7):2263-2279. doi: 10.4049/jimmunol.1700242. 2018.

168. Caponnetto S, Draghi A, Borch TH, Nuti M, Cortesi E, Svane IM, and Donia M. Cancer immunotherapy in

patients with brain metastases. Cancer Immunol Immunother, 67(5):703-711. doi: 10.1007/s00262-018-2146-8. 2018.

169. Andersen R, Borch TH, Draghi A, Gokuldass A, Rana MAH, Pedersen M, Nielsen M, Kongsted P, Kjeldsen

JW, Westergaard MCW, Radic HD, Chamberlain CA, Hölmich LR, Hendel HW, Larsen MS, Met Ö, Svane IM, and Donia M*. T cells isolated from patients with checkpoint inhibitor-resistant melanoma are functional and can mediate tumor regression. Ann Oncol, 29(7):1575-1581. doi: 10.1093/annonc/mdy139. 2018. * shared last authorship

170. Kverneland AH, Enevold C, Donia M, Bastholt L, Svane IM, and Nielsen CH*. Development of anti-drug

antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab. Oncoimmunology, 7(5):e1424674. doi: 10.1080/2162402X.2018.1424674. eCollection 2018. * shared last authorship

171. Kjeldsen JW, Donia M, and Svane IM. [Cancer immunotherapy]. Ugeskr Laeger, 180(21):2-6. pii:

V09170691. Danish. 2018.

172. Holmström MO, Riley CH, Skov V, Svane IM, Hasselbalch HC, and Andersen MH. Spontaneous T-cell responses against the immune check point programmed-death-ligand 1 (PD-L1) in patients with chronic myeloproliferative neoplasms correlate with disease stage and clinical response. Oncoimmunology, 7(6):e1433521. doi: 10.1080/2162402X.2018.1433521. eCollection 2018.